513LBA (PB-513) LBA Posters: BCCA7693 - A novel, orally bioavailable DNA-PK inhibitor demonstrates efficacy with targeted MAPK and PARP therapeutics by slowing the development of acquired resistance
Titel:
513LBA (PB-513) LBA Posters: BCCA7693 - A novel, orally bioavailable DNA-PK inhibitor demonstrates efficacy with targeted MAPK and PARP therapeutics by slowing the development of acquired resistance
Auteur:
Kyle, A. Baker, J. Banath, J. Teymori, S. Smiljanic-Hurley, E. Osborne, S. Sturino, C. Mancini, J. Paquette, J. Arns, S. Minchinton, A.